MISTIE III: A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage
Aims:
The purpose of this study is to determine the safety and effectiveness of an emergency treatment for intracerebral hemorrhage (spontaneous bleeding in the brain) as compared to current standard of care. The investigational treatment involves a procedure to remove the blood clot in the brain through a small tube, and the use of a drug called rt-PA, to break up the clot and further aid in its removal. Study participants will be randomly assigned to either the investigational treatment or current standard of care, which does not include removal of the clot.
Principal Investigator:
Shakeel Chowdhry, MD
IRB Approval Number:
EH13-028
Funding Source:
Johns Hopkins University/The National Institute of Neurological Disorders and Stroke (NINDS)
Contact:
Please call 847.570.4224 with questions regarding the study
Open to Enrollment:
Yes

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial
Aims: To determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg of clopidogrel is effective in preventing major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of transient ischemic attack (TIA) or minor ischemic stroke onset in patients receiving aspirin 50-325 mg/day (with a dose of 162 mg daily for 5 days followed by 81 mg daily strongly recommended).
Principal Investigator: Archie Ong, MD
IRB approval number: EH11-057
Funding source: The National Institute of Neurological Disorders and Stroke (NINDS)
Contact: Please call 847.503.4322 with questions regarding the study
Open to enrollment: Yes

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke
Aims: The purpose of this study is to evaluate the safety, tolerability and effectiveness of the investigational drug HT-3951 to treat the effects of stroke. HT-3951 is being studied as possible treatment in a number of neurological conditions, such as motor impairment (difficulty moving) after a stroke.
Principal Investigator: Archie Ong, MD
IRB Approval Number: EH15-341
Contact: Please call 847.503.4322 with questions regarding the study
Open to enrollment: Yes